Literature DB >> 6490225

Parenteral augmentin: pharmacokinetics.

D H Staniforth, D Jackson, R Horton, B Davies.   

Abstract

The pharmacokinetics of intravenous Augmentin have been investigated and the data found to fit a two compartment model. In the first study, to a crossover design, a bolus injection of 1.2 g Augmentin was given to 8 healthy volunteers with and without probenecid. It was found that the serum concentrations of amoxycillin were increased in the presence of probenecid, but those of clavulanic acid were unaffected. In a second study a further 8 volunteers received an infusion over 30 min of 2.2 g Augmentin. At the end of the infusion, peak concentrations in excess of 100 micrograms/ml were recorded for amoxycillin and 14 micrograms/ml for clavulanic acid. In both studies the serum and urinary concentrations of amoxycillin and clavulanic acid obtained were well above those considered necessary to achieve a therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490225

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  7 in total

1.  Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin.

Authors:  B E Davies; R Boon; R Horton; F C Reubi; C E Descoeudres
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.

Authors:  Stéphane Bronner; Valérie Murbach; Jean-Daniel Peter; Dominique Levêque; Hassan Elkhaïli; Yves Salmon; Nathalie Dhoyen; Henri Monteil; Gary Woodnutt; François Jehl
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 4.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

5.  Do augmentin or cefuroxime reach effective levels in lumbar vertebral discs when used prophylactically for discectomy? A preliminary report.

Authors:  P L Housden; M F Sullivan
Journal:  Eur Spine J       Date:  1993-10       Impact factor: 3.134

6.  Experience with parenteral and sequential parenteral-oral amoxicillin/clavulanate (augmentin) in hospitalized patients.

Authors:  W Büchi; P A Casey
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

7.  In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin.

Authors:  J Prieto; L Aguilar; M J Giménez; D Toro; M L Gómez-Lus; R Dal-Ré; I P Balcabao
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.